Isolate Data
| Patient | Isolate | Region | Year | Species | Subtype | Source | Clone Method |
| 3PoBV | 3PoBV33 | U.S. | 1994 | HIV1 | B | Plasma | MMC |
Treatment History
| Order | Regimen | Weeks |
| 1 | NRTI+IDV | 33 |
Protease Sequence
| PIMajorDRMs | PIMinorDRMs | Polys | UnusualMuts |
| M46L | L10I, L63Q, Q92R, I93L |
| >3PoBV33| 58 | codons 1-99 | clone 58 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQYD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| 59 | codons 1-99 | clone 59 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFTKVRQYD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| 60 | codons 1-99 | clone 60 PQITLWQRPIVTIKMGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQYD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| 61 | codons 1-99 | clone 61 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQHD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| 62 | codons 1-99 | clone 62 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQYD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| 63 | codons 1-99 | clone 63 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQYD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| 64 | codons 1-99 | clone 64 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQYD QIQIEICRHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| 65 | codons 1-99 | clone 65 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGLIKVRQYD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF >3PoBV33| codons 1-99 PQITLWQRPIVTIKIGGQLKEALLDTGADDTVLEEMNLPGRWKPKLIGGIGGFIKVRQYD QIQIEICGHKAIGTVLVGPTPVNIIGRNLLTRLGCTLNF |
References
| Author | Title | Citation |
| Zhang, Y-M | Drug resistance during indinavir therapy is caused by mutations in the protease gene and in its gag substrate cleavage sites. | J Virol, 1997 |
| Rhee, SY | HIV-1 Protease and Reverse Transcriptase Mutations: Correlations with Antiretroviral Therapy in Subtype B Isolates and Implications for Drug-Resistance Surveillance. | J Infect Dis, 2005 |